Skip to main content
Fig. 6 | Journal of Hematology & Oncology

Fig. 6

From: Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy

Fig. 6

Regulation of c-Myc expression by wild-type IDH2 in AML cells. a Effect of IDH2 knockdown on the expression of IDH2, C-MYC and its target gene Bcl-2 in U937 and ML-1 cells. Protein expression was analyzed by Western blotting. b Relative protein levels of C-MYC in U937 and ML-1 cells transfected with shRNA-Ctrl or shIDH2 vectors (#1 and #2). Data are representative of three separate experiments. c Relative mRNA level of C-MYC in U937 cells harboring shRNA-Ctrl or shIDH2 vectors. RNA expression was measured by RT-qPCR. d Relative mRNA level of C-MYC in ML-1 cells harboring shRNA-Ctrl or shIDH2 vectors. RNA expression was measured by RT-qPCR. e Expression of IDH2 protein and C-MYC protein in HL-60 cells transfected with control vector (Vector) or wt-IDH2 expression vector (IDH2OE), protein expression was detected by Western blotting. f Relative mRNA levels of C-MYC in HL-60 cells harboring control vector or IDH2OE vector, measured by RT-qPCR. g Representative images of C-MYC immunohistochemistry (IHC) staining of tumor tissues from U937 xenografts harboring shRNA-Ctrl or shIDH2 vectors (#1 or #2). The scale bars represent 100 μm. n = 3, mean ± SD, *p < 0.05, ***p < 0.001

Back to article page